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Abstract
Background: Short half-life and low levels of growth factors in the niche of injured microenvironment necessitates
the exogenous and sustainable delivery of growth factors along with stem cells to augment the regeneration of
injured tissues.
Methods: Here, recombinant human hepatocyte growth factor (HGF) was incorporated into chitosan nanoparticles (CNP)
by ionic gelation method and studied for its morphological and physiological characteristics. Cirrhotic mice received either
hematopoietic stem cells (HSC) or mesenchymal stemcells (MSC) with or without HGF incorporated chitosan nanoparticles
(HGF-CNP) and saline as control. Biochemical, histological, immunostaining and gene expression assays were carried out
using serum and liver tissue samples. One way analysis of variance was used for statics application
Results: Serum levels of selected liver protein and enzymes were significantly increased in the combination of
MSC and HGF-CNP (MSC+HGF-CNP) treated group. Immunopositive staining for albumin (Alb) and cytokeratin 18
(CK18), and reverse transcription-polymerase chain reaction (RT-PCR) for Alb, alpha fetoprotein (AFP), CK18,
cytokeratin 19 (CK19) ascertained that MSC-HGF-CNP treatment could be an effective combination to repopulate
liver parenchymal cells in the liver cirrhosis. Zymogram and western blotting for matrix metalloproteinases 2 and 9
(MMP2 and MMP9) revealed that MMP2 actively involved in the fibrolysis of cirrhotic tissue. Immunostaining for
alpha smooth muscle actin (aSMA) and type I collagen showed decreased expression in the MSC+HGF-CNP
treatment. These results indicated that HGF-CNP enhanced the differentiation of stem cells into hepatocytes and
supported the reversal of fibrolysis of extracellular matrix (ECM).
Conclusion: Bone marrow stem cells were isolated, characterized and transplanted in mice model. Biodegradable
biopolymeric nanoparticles were prepared with the pleotrophic protein molecule and it worked well for the
differentiation of stem cells, especially mesenchymal phenotypic cells. Transplantation of bone marrow MSC in
combination with HGF-CNP could be an ideal approach for the treatment of liver cirrhosis.
Introduction
Liver cirrhosis is irreversible in many cases and leads to
death if proper remedies are not taken. In recent years,
numerous articles have reported the regeneration of
hepatocytes or hepatocyte-like cells from stem cells
[1,2]. Regeneration of hepatocytes and improvement of
cirrhotic condition in mice followed by transplantation
of bone marrow MSC [3,4] and cross lineage differentia-
tion of HSC into hepatocytes [5-7] have been reported
earlier. The reason for the transplantation of stem cells
is to promote the regeneration of tissue specific cells
and subsequent morphological and functional recovery
of organs of all lineage cells [8,9]. Hence, bone marrow
stem cells could be used in all ailments associated with
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opportunities for stem cell therapy.
However, number of stem cells engrafted and differ-
entiated after transplantation limit the treatment stra-
tegies. Furthermore, ambiguity continues over the
contribution of which subpopulation of bone marrow
stem cells actually differentiate into hepatocytes and
restore the liver functions [10]. Moreover, the mechan-
ism by which stem cells regenerate the respective par-
enchymal cells, heading to repair of the organs in vivo
is yet to be completely understood. Cell fusion, in
which stem cells fuse with the somatic cell in the
niche, had been suggested by many authors [11] and
strong evidences were reported for the transdifferentia-
tion of stem cells [12].
Investigators attempted to improve cell therapy by a
number of strategies [13] and delivery of bioactive mole-
cules for example, growth factors, cytokines and chemo-
kines, is one among them. Tissue repair and functional
recovery after the transplantation of stem cells are aug-
mented by the delivery of bioactive molecules that
induce stem cells to differentiate into specific-lineage
cells. HGF has been reported to be a potent agent for
acceleration of tissue regeneration following an acute
insult, as well as amelioration of tissue fibrosis and dys-
function in chronic conditions [14,15]. Though secretion
of HGF after liver injury is increased, long-term secre-
tion in the adults is questionable. Subsequently, better-
ment of maintenance, proliferation and differentiation of
stem cells with exogenous supply of growth factors by
the injured liver has been reported [7].
Despite the pleotrophic effect of HGF [16], the long
term effects of exogenous HGF remain questionable
because of its short half-life period. As it is also rapidly
clearly by the liver in vivo, exogenous HGF is extremely
unstable in the blood circulation with a half-life of only
3-5 min [17,18]. This makes it almost impossible to sus-
tain a constant constantly high level of exogenous HGF
in the circulation, even with repeated injections of HGF
at short intervals. This necessitates the findings of the
efficient alternative means to effectively deliver growth
stimuli to the niche where it is needed for biological
actions. Nanotechnology offers solutions for the safe
and conducive transportation of therapeutic proteins to
the target site [19]. Chitosan, one among the biodegrad-
able and less antigenic natural polymers, was reported
to have the potential to carry and deliver the biologically
active macromolecules [20,21]. Hence, chitosan, in the
form of nanoparticles, can be used to deliver HGF with
less systemic dilution. Earlier our group has proven that
HGF could be released from CNP and thus released
HGF stimulated differentiation of MSC into hepatocyte-
like cells in vitro [22]. Here, we demonstrated, for the
first time, the ability of rhHGF incorporated CNP to
differentiate MSC into hepatocytes in vivo followed by
the decrease of severity of cirrhotic condition.
Materials and methods
Animal experiments
Six week old Balbc mice were purchased from Tamil
Nadu Animal and Veterinary University, Chennai, India.
Animal maintenance and handling was carried out as
per the guidelines of Institutional Animal Ethics Com-
mittee. To induce liver cirrhosis, 1.0 ml/kg body weight
of carbon tetrachloride (CCl4) mixed with olive oil (1:1
ratio) was injected intraperitonealy into female mice
twice a week up to four weeks. Site of injection was
changed on every dose to avoid necrosis of local skin
and to obtain invariable results. Isolation of stem cells:
MSC and HSC were isolated and characterized as per
protocol [23]. Isolated cells showed typical mesenchymal
and hematopoietic stem cell phenotypic characteristics.
Treatment protocol: One day after the eighth injection
of CCl4, MSC or sorted HSC with or without HGF-
CNP or saline as a control were injected into tail vein of
female mice. Either MSC or HSC of 1 × 10
6cells was
taken for injection. The amount of HGF-CNP taken for
injection was adjusted such that each mouse received
1 0 0n go fH G F .C C l 4w a si n j e c t e df o ra n o t h e rt w o
weeks after cell transplantation to maintain persistent
liver damage and six mice were sacrificed at predeter-
mined time interval after post-transplantation. Liver tis-
sue was collected after perfusing with 4%
paraformaldehyde solution and preserved in formalin
buffer solution for histopathological studies. For protein
and total RNA isolation, liver tissue was snap-frozen in
liquid nitrogen and then stored at -80°C.
HGF incorporated nanoparticle preparation and
characterization
CNP were prepared according to the protocol of Pan et.
al [24]. Briefly, 0.2% chitosan (Sigma Aldrich, USA)
solution was prepared in 1% glacial acetic acid (Sigma
Aldrich, USA). Nanoparticles were prepared by drop-
wise addition of 0.1% tripolyphosphate (TPP) (Sigma
Aldrich, USA) solution into chitosan solution with or
without HGF (R&D systems, USA). Turbidity was taken
as an indicator for the formation of nanoparticles and
the solution was subjected to centrifugation at 20,000
rpm for 20 min. The supernatant was discarded in the
control and saved in the case of HGF added to quantify
the amount of HGF in the supernatant by ELISA, using
Human HGF Quantikine ELISA kit (R&D systems,
USA) as per manufactures’ instructions. All measure-
ments were carried out in triplicate. Particle size and
the morphological characteristics of the nanoparticles
were examined using a high resolution transmission
electron microscope (HRTEM, JEM 3010, JEOL USA,
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tion containing nanoparticles was syringe placed on a
carbon film (300 mesh copper grid) allowing sitting
until air-dried. The sample was stained with 1% muranyl
acetate solution for 5 sec at 7°C before viewing on the
HRTEM.
Evaluation of HGF encapsulation and release
HGF-CNP prepared was taken into PBS of physiological
pH and kept in reciprocal shaking water bath at 37°C
and 35 rpm. At predetermined time intervals, the sam-
ples were subjected to centrifugation at 20000 rpm for
20 min at 4 °C and the supernatant was replaced by
fresh PBS. The amount of HGF released was quantified
by ELIZA. All measurements were carried out in tripli-
cate. The growth factor-loading efficiency of nanoparti-
cles and their entrapment efficiency were calculated
from the following equations:
Loading efﬁciency (%)
=

Total growth factor − Free growth factor

/Weight of nanoparticles

/ × 100
Entrapment efﬁciency(%)
=

Total growth factor − Free growth factor

/Total growth factor

/ × 100
Biochemical parameters
Serum was collected to analyze alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and Alb. Assays
were carried out at Lister Metropolis Laboratory, Chennai,
India using standard automated instrumentation.
Hydroxyproline assay
To estimate hydroxyproline content, freeze-dried liver
samples were hydrolyzed in 6N HCl in sealed tubes at
110°C for 18-24 h. The hydrolyzed samples were dried
over water bath and dissolved in water and then made
up to a known volume. The clear supernatant obtained
was used for the estimation of hydroxyproline content.
The assay of hydroxyproline content was performed
according to the method of Neuman and Logan [25]
and the amount was expressed in μg/g wet liver tissue.
Zymography assay
The liver protein sample (50 μg) was electrophorezed in
10% polyacrylamide gel containing 0.1% porcine skin gela-
tin without reducing agent. After separation, SDS was
removed from the gel by two washes each 15 minutes
with 1.5% Triton X-100. Subsequently, the gel was equili-
brated using developing buffer (50 mM Tris [pH 7.4], 200
mM NaCl, 10 mM CaCl2, 0.02% NaN3, 1 μM ZnCl2) for
30 minutes, and incubated in the fresh developing buffer
for 18-20 hr. The gel was stained with 0.25% coomasine
brilliant blue (CBB) R-250 followed by destaining.
Western blotting for MMP2 and MMP9 expression
The samples (50 μg) were resolved by 10% SDS PAGE
and protein was transferred to PVDF membrane (Amer-
sham, USA). After blocking with 5% nonfat milk, the
membrane was probed with anti-mouse MMP-2 (mAB,
Calbiochem, Germany). After vigorous washing with
TBS, the membrane was incubated with HRP-conju-
gated secondary antibody (Santacruz Biotechnology,
USA). Western blot was developed using diaminobenzi-
dine substrate (Sigma Aldrich, USA) and for MMP9
detection, the membrane was probed against goat anti-
mouse MMP9 (pAB, Sigma Aldrich, USA), followed by
anti-goat secondary antibody for 1 hr and then, the
color was developed using BCIP/NBT liquid substrate
system (Sigma Aldrich, USA). The blot was photo-
graphed and semi-quantitative estimation was carried
out.
Sirius red and H&E staining
Paraffin fixed liver tissue was sectioned 5 μms i z ea n d
then, the sections of liver tissue (5 μm) were stained
with hematoxylin and eosin dyes for histological study.
For sirius red staining, paraffin sections of 5 μmt h i c k -
ness were dewaxed and rehydrated and then, were
stained with 0.1% sirius red (Direct Red, Sigma Aldrich,
USA) in saturated solution of picric acid. Staining was
photographed by light microscope (Nikon, Japan).
Immunofluorescence assay
For immunofluorescence assay, paraffin fixed liver tissue
was sectioned into 5 μms i z ea n dt h e n ,t h es e c t i o n s
were deparaffinised and hydrated. After quenching
endogenous peroxidase activity with 0.3% H2O2 in
methanol, blocking was carried out using bovine serum
albumin (Sigma Aldrich, USA). The blocked sections
were incubated overnight at 4°C against mouse Alb
(pAB, abcam, USA), CK 18 and Type I collagen (mAB,
Santacruz Biotechnology, USA) and a-SMA (mAB,
Sigma Aldrich, USA) antibodies. The sections were
incubated with FITC conjugated secondary antibodies
for 15 minutes and then the slides were viewed under
fluorescence microscope (Hund Wetslar, Germany). In
between steps, slides were washed with PBS.
Reverse transcription PCR analysis
Total RNA was isolated from snap frozen liver tissue
using Trizol reagent (Sigma Aldrich, USA) and the ratio
of absorbance values at 260 and 280 nm indicated an
estimate of RNA purity. RT-PCR was performed using
one-step RT-PCR kit (Qiagen K.K., Tokyo, Japan) with
the following primers: CK18 S: A: 5’-TGGTACTC
TCCTCAA TCTGCTG-3’,A : 5 ’-CTCTGGATTGACT
GTGGAAGTG-3’ (148 bp), CK19 S:5’-CATGGTTCT
TCTTCAGGTAGGC-3’,AS : 5 ’-GCTGCAGATGAC
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GAGCAGAGAAGC-3’,A :5 ’-AGACTGCCTTGTGTG-
GAAGACT-3’, (145), AFP S: 5’-GTGAAACAGACTT
CCTGGTCCT -3’,A :5 ’-GCC CACAGACCATGAAA-
CAAG-3’(bp148). RT-PCR was used to evaluate chimer-
ism in mouse liver tissue after sex mismatched stem cell
transplantation. Male derived MSC and HSC were trans-
planted into female mice. Primers for sry gene specific
for mouse testis were selected from the previous study.
Forward and reverse primers were as follows: F5’AGA-
GATCAGCAAGCAGCTGG 3’,R 5 ’ TCTTGCCTGTA
TGTGATGGC 3’ (bp248).PCR reactions were per-
formed according to manufacturer’s instruction with
each cycle in a Eppendorf Thermal Cycler (Takara,
Tokyo, Japan) using appropriate cycle profile. After the
reaction, aliquots of the product were run on 1% agar-
ose gel, stained with ethidium bromide. The amount of
amplified product was quantified for each sample using
a computing densitometer (Gel Doc EQ Gel documenta-
tion System; Biorad Laboratories, Hercules, CA) and
software (Quantity One). The final amount of PCR pro-
duct was expressed as the ratio of the respective gene
amplified to that of the bactin gene, to account for any
differences in beginning amounts of RNA.
Data Analysis
Experimental results were expressed as mean±S.D. Ana-
lysis of variance was performed by one way analysis of
variance procedures (SSPS 9.0 for Windows). Significant
differences between means were determined by Dun-
nett’s post hoc test.P < 0.05 implies statistical signifi-
cances. For histopathological assays, the sections were
taken from multiple samples at various locations. The
best out of these figures is given for representation in
each group.
Results
Physicochemical characteristics of HGF incorporated
nanoparticles
Morphological characteristics of CNP and the release
pattern of HGF from CNP were studied. The loading
efficiency of nanoparticles and entrapment efficiencies
of HGF were 5 ng HGF/mg of nanoparticles and 85%
respectively. This was achieved with chitosan to TPP
ratio at 2:1. At lower ratio, more protein could be incor-
porated since more positive charge from chitosan will be
available. Care was taken not to form crystal-like parti-
cles during the preparation. Plain and HGF loaded
nanoparticles observed by HRTEM (Figure 1 A and 1B)
appeared spherical in shape with a particle size range of
50-100 nm. The in vitro release profile of HGF from the
nanoparticles in PBS at the predetermined time was
expressed as percentage of HGF released with respect to
the total amount of HGF encapsulated (Figure 1C).
HGF release observed after 24 and 35 days was 82 and
85% respectively, indicating the monophasic release pat-
tern of nanoparticles over a period of at least 25 days.
This indicates that physical adsorption of the growth
factor on the nanoparticles is unlikely, which is an
essential characteristic feature for the nanoparticles
required for sustained release.
MSC-HGF-CNP improved liver morphology, function and
hepatocytes proliferation
The liver samples of control and HSC treated groups
appeared pale and shrunken and the samples treated
with MSC/+HGF-CNP were reddish brown and normal
(data not shown). The liver function tests of each group
after fourth week of transplantation was assessed by
analyzing the serum levels of Alb, ALT and AST and
the results are presented in Table 1. Elevated levels of
Alb and aminotransferase enzymes were found in con-
trol, HSC and HSC+HGF-CNP treated groups. Signifi-
cant increase of Alb (2.5 ± 0.03d, dP < 0.001) and
decreased levels of ALT (95 ± 5d,dP < 0.001) and AST
(510 ± 15c, cP < 0.05) were found in the MSC/+HGF-
CNP treated group. These findings indicated that MSC/
+HGF-CNP treatment induced the secretion of these
liver specific proteins.
To verify hepatic differentiation of transplanted stem
cells and subsequent recovery of liver cirrhosis, the
expression of liver markers such as Alb and CK18 was
Figure 1 Chracterization of nanoparticles: High resolution TEM of
(A) chitosan nanoparticles (B) HGF incorporated nanoparticles.
Particles are flat and round shape (C). Cumulative release pattern of
HGF from CNP. Sustainable release of growth factor could be seen
from the release curve. Values are presented as mean ± S.D for
triplicate experiment.
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taining. Alb and CK18 proteins increasingly expressed
in the MSC/+HGF-CNP treated group compared to
other groups (Figure 2A and 2B) despite continuous
injection of CCl4 after post-transplantation. On the
other hand, the expression of these markers was less in
the control and HSC/+ HGF-CNP treated groups. This
observation is in good correlation with the results of
biochemical parameters. The results of both biochemical
and immunohistochemical studies were further con-
firmed by the expression of mRNAs of Alb, CK18, AFP
and CK19 proteins (Figure 3A). In semiquantitative ana-
lysis of gene expression, all of these genes expressed sig-
nificantly (P < 0.05). HSC, even in the presence of HGF-
CNP, did not show significant increase in the expression
of these proteins and their levels were observed to be
less than in MSC treated groups. Analysis of chimerism
after cell transplantation is important for assessing the
graft by the presence of donor cells. It is usually
detected by the expression of specific gene by donor
cells. Sry gene from donor male cells was detected by
RT-PCR. Sry gene was expressed in all treatment
groups; however, the control group did not show sry
gene expression (Figure 3C).
In control and HSC treated groups, these genes were
not expressed significantly. From this, it was confirmed
that the transplanted MSC were able to differentiate
into liver parenchymal cells, wherein HGF-CNP
enhanced the process of differentiation. Wang et al
(2003) showed that hepatic differentiation of HSC could
be enhanced by intravenous injection of soluble HGF.
None of the earlier reports explained the receptor
mechanism or pathways with which HGF facilitates the
differentiation of HSC after transplantation. Sry gene
expressed in all transplantation experiments except con-
trol (Figure 3C). RT-PCR result for engraftment shows
that chimerism in HSC treated mice is possible but the
exact place where the transplanted cells is oriented is
still questionable and whether undifferentiated HSC or
differentiated parenchymal cell or differentiated nonpar-
enchymal cell contribute for the chimerism is also to be
understood.
Histology and collagen content
Fibrotic conditions were assessed after fourth week of
transplantation using sirius red staining and hyproxy-
proline content of the cirrhotic tissue. The representa-
tive images for fibrosis are shown in Figure 4A.
Distribution of fibrosis was extensively reduced in MSC/
+HGF-CNP group followed by MSC alone compared to
control, HSC or HSC+HGF-CNP treated groups. Quan-
tification of fibrosis by image analysis (Figure 4B) clearly
indicated that the level of fibrosis has been significantly
reduced in MSC, 4.56 ± 0.29 (P < 0.05) and MSC+HGF-
CNP, 2.15 ± 0.14 (P < 0.01) treated groups but not in
HSC (6.89 ± 0.24) or HSC+HGF-CNP (5.89 ± 0.18)
groups compared to control. The hyproxyproline con-
tent (Figure 4C) in HSC or HSC+HGF-CNP treated
groups did not show significant difference from the con-
trol group; however in the case of MSC or MSC+HGF-
Figure 2 Immunofluoresent expression: After 4
th week of post-transplantation, the liver was perfused with 4% paraformaldehyde solution and
stored in 10% buffered formalin solution. After dewaxing and dehydrating, the sections were incubated overnight with anti-mouse Alb (A) and
CK18 (B) antibodies and the expression of these proteins was viewed by fluorescent microscopy using secondary antibody tagged with FITC.
Both Alb and CK18 were highly expressed in MSC and MSC+HGF-CNP treated groups but not in control, HSC and HSC+HGF-CNP treated groups.
It displayed the differentiation of MSC and augmentation of differentiation by HGF-CNP (Control magnification 100 ×).
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significantly low compared to the control (P < 0.01).
These results provided direct evidence for an antifibrotic
effect of MSC and MSC + HGF-CNP combination. Fig-
ure 4D shows the histology of liver tissue of control and
treated groups. The microscopical view of the H&E
stained specimens revealed the appearance of disrupted
tissue architecture with large fibrous septa and infiltra-
tion of inflammatory and necrotic cells in the liver sec-
tions of control, HSC or HSC+HGF-CNP treated groups
but not in MSC and MSC+HGF-CNP treated groups.
MSC suppress the activation of hepatic stellate cells
Inflammatory cascade activates the quiescent hepatic
stellate cells into myofibroblasts which was confirmed
by the immunostaining of a-SMA (an indicator of acti-
vated myofibroblasts). Secretion of type I collagen by
myofibroblasts that leads to fibrosis was analyzed by
immunofluorescence. The results of imunofluorescence
study for distribution of a-SMA positive cells around
the sinusoid portion (Figure 5A) confirmed the histolo-
gical observation (Figure 4D) in respect of the presence
of large number of nonparenchymal cells with consistant
morphology of activated myofibroblast-like cells clus-
tered around the fibrotic septae at the end of fourth
week in control, HSC or HSC+HGF-CNP treated
groups. Increased expression of a-SMA in the periportal
region of liver of control, or HSC+HGF-CNP treated
groups and the reduced expression of this protein in
MSC and MSC+HGF-CNP groups were also noticed.
Decreased expression of type I collagen, due to reduced
myofibroblast activity, in MSC or MSC+HGF-CNP com-
pared to control and other treated groups is shown in
Figure 5B.
MMPs activity and expression
The fibrolytic activity of MMPs and their expression are
depicted in Figure 6A and 6B respectively. The zymo-
graphy assay revealed a band of gelatin degradation at
68 kDa, representing active MMP-2 and another band
at 97 kDA representing MMP9 (Figure 6A). The MSC
groups, particularly MSC+HGF-CNP, showed increased
expression of MMPs, more especially MMP2. The over-
all data on the quantitative analysis of MMP9 (Figure
6C) and MMP2 (Figure 6D) indicated that MMP9 was
relatively less expressed and active compared to MMP2.
Figure 3 Gene expression of liver proteins: (A) Total RNA was isolated using Trizol agent and after quality verification, PCR was carried out
using PCR kit and the products were run on 1% agarose gel to analyse the expression of genes of Alb, AFP, CK18 and CK19. Lane:1 Control,
Lane:2 HSC, Lane:3 MSC, Lane:4 HSC+HGF-CNP, Lane:5 MSC+HGF-CNP. All these genes were highly expressed in MSC treated groups compared
to control and HSC treated groups. (B) Semiquantification of liver specific proteins - mRNAs Alb, AFP, CK18 and CK19 of control and treated
groups were significantly expressed in MSC and MSC+HGF-CNP treatment. In control and HSC treated groups, expressions were not significant.
(C)RT-PCR expression of sry gene (Male Y chromosome specific gene). Sry gene is expressed in all treated groups, showing the presence of
chimerism. in all groups.
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The present study described the effect of HGF-CNP on
the in vivo hepatic differentiation of stem cells. Earlier,
increased expression of Alb was reported after exogen-
ous injection of rhHGF in mice [7]; however, in vivo
availability of HGF was not considered in the study
since its half-life period is very short [17,18]. To main-
tain adequate level of serum HGF and overwhelming its
short half-life period, repeated injection of HGF [26]
and/or its gene [27] was suggested. In this study, we
have incorporated HGF into CNP by ionic gelation
method. Such particles can carry the therapeutic pro-
teins to the targeted site without degradation and can
sustain in the circulatory system. The protonated amino
groups of chitosan as well as HGF in the acidic medium
electrostatically combined with anions of TPP to form
cross-linkage and this procedure ensured the systemic
incorporation of growth factor into the nanoparticles
instead of adsorption. Nanoparticles having the size
range of 50-200 nm could be used effectively for the
biological application by injecting them intravenously
because they are capable of reaching multiorgans for
therapeutic application [28]. CNP with 50-200 nm size
prepared in this study (Figure 1) showed sustainable in
vitro release up to 24 days as against the earlier report
where the release was observed only for 8 days [29].
The cumulative release of 82% of HGF after 24 days
observed in our study indicated an extended time course
for sustainable release ruling out the possibility of either
biphasic or burst release. This level of controlled release
Figure 4 Histological appearance of the liver: (A) Expression of collagen was viewed by sirius red staining: Collagen bridge was uniform in
control and HSC treated groups but not in MSC and MSC+HGF-CNP treated groups (original magnification × 100). (B) Quantitative analysis of
fibrosis is shown in histographic representation. The degree of fibrosis was expressed as the percentage of the total area measured. The fibrosis
areas were significantly low in MSC and MSC+HGF-CNP treated groups (P < 0.05). However there were no statistical differences in liver fibrosis
between control and HSC treated groups. (C) Hydroxyproline content was estimated by Neuman and Logan method. Hydroxyproline content
did not vary significantly between control and HSC treated groups and but was significantly low in MSC and MSC+HGF+CNP groups (P < 0.05).
(D) Formalin fixed liver tissues were sectioned into 5 μm size and stained with H&E dyes. Infiltration of inflammatory and necrotic cells was
ubiquitous in control and HSC treated groups however, MSC treated groups did not show inflammatory cells (original magnification ×100)
Control (1); HSC (2); MSC (3); HSC+HGF-CNP (4); MSC+HGF-CNP (5).
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ferentiation of stem cell as has been observed by
Hasuike et al. [30]. Another important feature of this
study was the effective use of HGF to a level of, as low
as, 1.2 μgH G F / m gC N P / k gb o d yw e i g h t ,a g a i n s t2 5 0
μg/Kg body weight [31] and 300 μg/Kg body weight [26]
reported earlier.
Less engraftment of transplanted cells necessitated the
findings of effective strategies which can differentiate
and expand the transplanted cells. The process of migra-
tion of MSC to the target site was reported to be guided
and accelerated in the presence of HGF [32]. the histo-
logical findings of our present study suggests that the
exogenous HGF prevent the hepatocytes from necrosis
and accelerated regeneration [27] as was observed in
our histological results. Results of these previous studies
brought forth the idea of delivery of HGF through car-
riers, especially nano-carrier, to aid the targeted as well
as sustainable delivery. In this study we report that HGF
released from HGF-CNP could also accelerate the
migration of MSC to injured liver and also facilitated its
hepatic differentiation, as only these cells have c-met
receptor for HGF. This was supported from the results
of increased expression of liver specific proteins and
their genes (Figure 2 and 3). From these results, it was
confirmed that the transplanted MSC were able to dif-
ferentiate into liver parenchymal cells, wherein HGF-
CNP helped to enhance the differentiation. Wang et al.
[7] showed that hepatic differentiation of HSC could be
enhanced by intravenous injection of soluble HGF.
None of the earlier reports explained the receptor
mechanism or pathways with which HGF facilitates the
differentiation of HGF after transplantation.
Differentiation of homed stem cells at the target site
was monitored by the expression of sry gene after trans-
plantation of stem cells in sex mismatched mice. The
expression of sry gene confirmed the engraftment of both
HSC and MSC in the recipient’s liver. RT-PCR result for
engraftment showed that chimerism in HSC treated mice
is possible but the exact place where the transplanted
cells is oriented is still questionable and which undiffer-
entiated HSC or differentiated parenchymal cells or dif-
ferentiated nonparenchymal cell contributed for the
chimerism is also to be understood. Higher expression of
sry gene observed in the MSC+HGF-CNP treated group
ascertained the migration followed by engraftment for
the effective repopulation of tissue-specific hepatocytes.
The HGF-incorporated chitosan nanoparticles can pre-
sumably work for the differentiation process in two ways:
injected HGF-incorporated nanoparticles may release the
growth factor in the circulation during the controlled
enzymatic degradation of biopolymers and thus released
HGF may enhance the differentiation; secondly, the liver
being the homing organ for any foreign particles, the
CNP upon reaching the liver is degraded to release the
growth factor which can induce the differentiation.
Figure 5 Immunofluoresent expression of ECM proteins: After 4th week, livers were harvested after perfusing with 4% paraformaldehyde
solution and stored in 10% buffered formalin solution. For immunofluoresence assay, the specimens after dewaxing and dehydrating were
blocked for nonspecific protein using BSA. Then, the sections were incubated overnight with anti-mouse a-SMA antibody (A): Control (A1), HSC
(A2), MSC (A3), HSC+HGF-CNP (A4) and MSC+HGF-CNP (A5); and anti-mouse type I collagen antibody (B): Control (B1), HSC (B2), MSC (B3), HSC
+HGF-CNP (B4) and MSC+HGF-CNP (B5). The expression of these proteins was viewed by fluorescent microscopy using secondary antibody
tagged with FITC. Both a-SMA and type I collagen expressed high in control, HSC and HSC+HGF-CNP treated groups than MSC and MSC-HGF-
CNP treated groups. MSC treatment suppressed the myofibroblasts and consequently made type I collagen disappeared (original magnification
×100).
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pressed or stopped to prevent progression of fibrosis.
Hepatic injury activates the secretion of cytokines of
inflammatory cascade from the multiple inflammatory
as well as parenchymal cells, which involve the healing
process. Suppression of inflammatory cytokines could
reduce the activation of hepatic stellate cells. Inhibition
of the proliferation of T cells thereby modulating the
pro-inflammatory cytokines such as TNF-a and IL1bby
MSC was reported [33-35]. Less invasions of inflamma-
tory cells in the MSC and MSC-+HGF-CNP treated
groups connect with the anti-inflammatory action of
MSC. Moreover, the direct involvement of MSC in
immunomodulation of hepatic stellate cells has also
been explored recently [36]. Lower level of a-SMA
positive cells in MSC treated group (Figure 5) is attribu-
ted to the anti-inflammatory activity of MSC that
secrete compounds which would have reversed myofi-
broblasts through paracrine mechanisms.
Most of the previous studies involving the transplanta-
tion of stem cells for therapeutic purpose, concentrated on
either functional recovery of liver from metabolic disease
in the knockout model [37] or the fibrolysis of ECM con-
tent [38]. For better understanding we have compared the
contribution of either HSC or MSC in the process of
reversal of cirrhosis in the liver. A significant difference
was observed in collagen content between MSC and HSC
treated groups or control (Figure 4). The disappearance of
collagen content in the cirrhotic liver of MSC groups was
apparently due to the lysis of fibrotic tissue which was
Figure 6 Expression of MMPs: (A) The activity of MMPs was analysed by zymography. The liver homogenate was resolved in 10% SDS-PAGE
containing 0.1% gelatin without reducing agent. The gel was then stained and washed. MMPs were well expressed in MSC and MSC+HGF-CNP
groups; particularly, MMP2 was increasingly expressed in these groups compared to control, HSC and HSC+HGF-CNP treated groups. This
indicated the activation of MMPs by MSC. (B) Expression of MMPs was analyzed by western blotting. Electrophoretically resolved proteins were
transferred and then immunostained against mouse MMP2 and MMP9. Control group 1, HSC 2, MSC 3, HSC+HGF-CNP 4, MSC+HGF-CNP 5
treated mice showed increased expression of MMPs, particularly MMP2. Semiquantitative analysis of MMP2 and MMP9 was carried out and
significant level of expression of MMP2 and MMP9 was found in MSC and MSC+HGF-CNP treated groups (P < 0.05) compared to control, HSC
and HSC+HGF-CNP treated groups. Significant level of expression of MMP2 appeared compared to MMP9. It explored the reason for the
decrease of ECM.
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the MMP2 that promote the degradation of ECM in liver
cirrhosis [39] should have been secreted by MSC, which in
the presence of HGF exhibited increased MMP2 activity,
as observed by enhanced fibrolysis and/or prevention of
collagen synthesis. This would have facilitated the assem-
bling and orientation of stem cells in the hepatic nodules
where they can differentiate into functional hepatocytes.
Though HSC can differentiate and recover the liver func-
tions to some extent, they obviously failed to degrade the
ECM. The expression of MMPs by HSC either in in vitro
or in vivo studies has not been reported so far. But it was
reported that transplanted HSC activate T lymphocytes
leading to inflammatory complications and posing health
risk in hematopoietic stem cell therapy [40]. Moreover, in
the cirrhotic liver, therapeutic strategies must rely on
achieving repopulation of liver parenchymal cells and
increased ECM degradation [41]. The potential of MSC
for differentiation, immune-suppression and the secretion
of matrix degradation molecules suggested that MSC
based cell therapy could be used successfully for the treat-
ment of liver inflammation and cirrhosis. This model
could also be extended to the reversal of other fibrotic
condition. Our further study will be extended in the direc-
tion of in vivo kinetics, distribution and stability of HGF-
CNP in the blood circulation. Whether HGF released
from the CNP causes the stem cell differentiation or apop-
tosis of myofibroflasts or both of these functions must be
studied in detail with the appropriate controls such as
HGF, CNP and HGF-CNP alone to derive the concept to
meaningful clinical applications.
Conclusions
Enhancement of regenerative effects of stem cells for the
treatment of tissue injuries and genetic developmental dis-
eases could be carried out with the multiple strategies such
as gene therapy, delivery of therapeutic proteins etc. Devel-
opment of biodegradable delivery devisees for the regenera-
tive medicine is the urgent need to compensate/enhance
the slow differentiation of stem cells. HGF incorporated
CNP prepared in this investigation showed appreciable
morphological and kinetic properties and it enhanced the
differentiation of stem cells in vivo, especially mesenchymal
phenotypic cells. Transplantation of bone marrow MSC in
combination with HGF-CNP was seen as an ideal approach
for the treatment of liver cirrhosis. This study will be
extended in the direction of in vivo kinetics, distribution
and stability of HGF-CNP to focus further on the localized
delivery with the receptor mechanism.
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